

Effectiveness of a pharmacist-driven intervention in chronic obstructive pulmonary disease

Submission date 02/03/2016	Recruitment status Stopped	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 04/03/2016	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 29/04/2019	Condition category Respiratory	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Chronic obstructive pulmonary disease (COPD) is the name for a collection of lung diseases which cause breathing difficulties. Patients with COPD often don't take their medications exactly as prescribed and have difficulty using their inhalers properly. Community pharmacists can help improve quality of life and overall health in these patients. We will study the effect that pharmacists can have on the health of patients with COPD. We hope to show that pharmacists can help improve the use of medications, inhaler technique and quality of life, and decrease health care costs and how many times COPD makes the patients sick.

Who can participate?

COPD patients, at least 40 years old

What does the study involve?

Participating pharmacies are randomly allocated to either provide the care they would normally offer on a daily basis, or to deliver an improved form of care that focuses on COPD management.

What are the possible benefits and risks of participating?

We hope to see an improvement in how well and how often people are remembering to take their medications, compared to before the study started. The only identified risks are the potential for the patient to feel overwhelmed during the data collection process.

Where is the study run from?

This study will take place in pharmacies in Newfoundland and Labrador (NL), Canada.

When is the study starting and how long is it expected to run for?

July 2015 to November 2017

Who is funding the study?

Health Research Foundation (Canada)

Who is the main contact?

1. Dr Erin Davis (emdavis@mun.ca)
2. Dr John Hawboldt (hawboldt@mun.ca)

Contact information

Type(s)

Scientific

Contact name

Dr Erin Davis

ORCID ID

<https://orcid.org/0000-0002-4925-1447>

Contact details

School of Pharmacy, Memorial University of Newfoundland
75 Tiffany Court
St. John's, NL
Canada
A1A 0L1
+1 (0)709 777 7232
emdavis@mun.ca

Type(s)

Scientific

Contact name

Dr John Hawboldt

Contact details

School of Pharmacy
Memorial University of Newfoundland
Health Sciences Centre
300 Prince Philip Parkway
St. John's, NL
Canada
A1B 3V6
+1 (0)709 777 8777
hawboldt@mun.ca

Additional identifiers

Study information

Scientific Title

Effectiveness of a pharmacist-driven intervention in chronic obstructive pulmonary disease (EPIC): a pragmatic cluster randomized controlled trial

Acronym

EPIC

Study objectives

Community pharmacists can help improve health-related quality of life and overall outcomes in patients with chronic obstructive pulmonary disease (COPD) through a pharmacist-driven intervention on: medication adherence, inhaler technique, health-related quality of life, health care resource utilization, COPD exacerbations, and use of medications.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Newfoundland and Labrador Health Research Ethics Board, 14/05/2015, approval number: 15 091

Primary study design

Interventional

Study design

Pragmatic cluster randomized controlled trial

Study type(s)

Other

Health condition(s) or problem(s) studied

Chronic obstructive pulmonary disease

Interventions

We will compare pharmacies delivering an improved form of care that focuses on COPD management with pharmacies providing the care they would normally offer on a daily basis.

Multifactorial pharmacist-led intervention on medication adherence, inhaler technique, health-related quality of life, health care resource utilization, COPD exacerbations, and use of medications. The intervention involves 6 main strategies:

1. Medication review
2. Patient education
3. A written COPD action plan provided in collaboration with their family physician
4. Patient referral to pulmonary rehabilitation in collaboration with their family physician
5. Provision of, or referral to, smoking cessation counseling (where applicable)
6. Referral to a community-based chronic disease self-management program

Intervention Type

Other

Primary outcome(s)

Change from baseline to 6 months in medication adherence using the medication possession ratio (MPR) and the Morisky Medication Adherence Scale (MMAS-8)

Key secondary outcome(s)

1. Proportion of patients with a clinically significant change in adherence
 2. Proportion of patients defined as having 'good adherence'
 3. Mean MPR between groups
 4. Quality of life as measured by the St. George's Respiratory Questionnaire
 5. Medication inhalation technique using a pharmacist-scored checklist
 6. Healthcare resource utilization
 7. Antibiotic and oral corticosteroid use for COPD exacerbations
- Measured at baseline and 6 months.

Completion date

01/11/2017

Reason abandoned (if study stopped)

Participant recruitment issue

Eligibility

Key inclusion criteria

1. Physician-diagnosed COPD
2. Age ≥ 40 years at trial enrollment
3. Sufficient ability to answer questionnaires in English

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. A known Forced Expiratory Volume in 1 second (FEV1)/ Forced Vital Capacity (FVC) of $< 30\%$
2. A diagnosis of dementia or a prescription for cholinesterase inhibitors
3. A terminal illness
4. Physician-diagnosed asthma
5. Participation in another clinical trial
6. If they do not provide consent

Date of first enrolment

01/05/2016

Date of final enrolment

01/05/2017

Locations

Countries of recruitment

Canada

Study participating centre

Memorial University of Newfoundland

School of Pharmacy

Memorial University of Newfoundland

Health Sciences Centre

St. John's, Newfoundland

Canada

A1B 3V6

Sponsor information**Organisation**

Memorial University of Newfoundland (Canada)

ROR

<https://ror.org/04haebc03>

Funder(s)**Funder type**

Research organisation

Funder Name

Health Research Foundation

Alternative Name(s)

Fondation pour la Recherche en Santé, HRF, FRS

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

Canada

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	13/10/2016		Yes	No